

BARRY J. MILLER PLLC
ATTORNEY AT LAW
850 EMMONS AVENUE
BIRMINGHAM, MI 48009

TEL.: +1 (248) 232-8039
FAX: +1 (248) 246-9524
E-MAIL: BJMILLER@BJMPLLC.COM

January 25, 2018

OTC Markets Group Inc.
304 Hudson Street
New York, NY 10013

Re: A Clean Slate, Inc.
Trading symbol: DRWN

Ladies and Gentlemen:

We are acting as special securities counsel to A Clean Slate Inc., a Delaware corporation having its executive offices at 14090 Southwest Freeway, Suite 300, Sugar Land, TX 77478 (the "Issuer"), to provide this letter with respect to the information (the "Information") publicly disclosed by the Issuer and published through the OTC Disclosure and News Service (the "Service"), including all information published at <http://www.otcmarkets.com/stock/DRWN/filings> (the "Filings Page") and related pages. The Issuer's common stock (the "Shares") is quoted on the OTC Pink tier maintained by OTC Markets Group Inc ("OMG"). OMG may rely on this letter in determining whether the Issuer has made adequate current public information publicly available within the meaning of Rule 144(c)(2) under promulgated by the United States Securities and Exchange Commission (the "SEC") under the Securities Act of 1933 ("Securities Act"). It should be noted that Rule 144(c)(2) (i) does not define or provide a standard for public availability of information and (ii) does not require publication of information on or through the Service.

The Information includes and is limited to information under the Issuer's control on the "Company Profile" page and the items of information indexed on the Filings Page, as follows:

1. Initial OTC PINK Basic Disclosure Statement for the period ended December 31, 2017, posted on the Service on January 24, 2018.
2. Quarterly Report for the period ended March 31, 2017, posted on the Service on January 24, 2018.
3. Quarterly Report for the period ended June 30, 2017, posted on the Service on January 24, 2018.
4. Quarterly Report for the period ended September 30, 2017, posted on the Service on January 24, 2018.
5. Annual Report for the year ended December 31, 2017, posted on the Service on January 24, 2018.

Such items are referred to herein as the "Items."

We are resident in the United States of America. From time to time, we have provided and expect to provide legal services to the Issuer in the areas of corporate, business transactions and securities law. We now have and have had any other relationship with or to the Issuer. We are licensed to

OTC Markets Group Inc.
January 25, 2018
Page 2

practice law in the States of New York and Michigan and are expert in the General Corporation Law of the State of Delaware (the “GCL”) and the federal securities laws of the United States of America. The subject matter of this letter covers the jurisdiction of the State of Delaware, the Issuer’s jurisdiction of incorporation, and is specifically limited to matters under the GCL and the federal securities law of the United States of America. We have not relied on the work of any other attorney in rendering the opinion set forth below. We are permitted to practice before the SEC and are not and have never been prohibited from such practice.

We have reviewed and relied upon, to the extent that we deem relevant to the opinions expressed herein, and relied upon the following:

- (i) The following publicly available documents:
 - (a) Copies of the certificate of incorporation the Issuer and all amendments thereto;
 - (b) the bylaws of the Issuer, as amended; and
 - (c) the Items;
- (ii) Advice given to us today by the Issuer’s transfer agent via email stating that the number of issued and outstanding Shares is 7,780,898,915 (the “Transfer Agent Advice”), which is not publicly available.

We have also reviewed and relied upon such other documents and certificates of the Issuer and of public officials as we have deemed necessary and relevant to the subject matter of this letter and have made such examination of law as we have deemed necessary in order to express the opinions rendered by this letter. We have assumed the due and proper election or appointment and legal capacity of all persons signing and purporting to sign the documents in their respective capacities, as stated therein, the genuineness of all signatures, the conformity to authentic original documents of the copies of all such documents submitted to us as certified, true, conformed and photocopied, including the quoted, extracted, excerpted and reprocessed text of such documents. As to matters of fact, we have relied on information obtained from public officials, officers of the Issuer and other sources that we believe to be reliable.

We have also reviewed and am familiar with Rule 144 under the Securities Act and Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”). It should be noted that the only information required by Rule 144(c)(2) that is required to be publicly available is limited to the information identified in paragraphs (a)(5)(i) to (xiv) and (a)(5)(xvi) of Rule 15c2-11. The required information is less extensive than the information identified in OTC Pink Basic Disclosure Guidelines v1.1 dated April 25, 2013. It should be noted that the OTC Markets “Alternative Reporting Standard” is a voluntary, privately operated system unrelated to and less comprehensive than the system of reporting pursuant to Sections 13 and 15(d) of the Exchange Act and the rules promulgated thereunder.

Based upon the foregoing, we are of the opinion that the Information (i) constitutes “adequate current public information” concerning the Shares and the Issuer and “is available” within our understanding of the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation

BARRY J. MILLER PLLC

OTC Markets Group Inc.
January 25, 2018
Page 3

for the Securities under Rule 15c2-11, (iii) complies as to form with OTC Pink Basic Disclosure Guidelines v1.1, dated April 25, 2013, and (iv) has been published through the Service.

We have been advised by the Issuer that (i) Ricky E. Bernard, the president and chief financial officer of Quantum Medical Transport, Inc., is responsible for preparation of its financial statements posted on OTC Markets Service, which are unaudited, (ii) he has 20 years of experience in senior business management and operations management, as well as considerable experience in financial reporting at the corporate level and (iii) he is the primary officer reviewing and approving the Issuer's financial statements.

The Company's transfer agent is Pacific Stock Transfer Company, the address of which is 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119. The transfer agent is registered with the SEC.

Through conference telephone we have (i) personally met with management and the sole director of the Issuer, (ii) reviewed the Information, as amended, published by the Issuer through the Service and (iii) discussed the Information with management and the sole director of the Issuer. In confirming the number of outstanding Shares, we have relied upon the TA Advice.

To the best of our knowledge, after inquiry of management and the sole director of the Issuer, neither of the Issuer, any holder of 5% or more of the Issuer's securities is, nor are we, currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

No person other than OTC Markets Group Inc. is entitled to rely on this letter. Notwithstanding this limitation on reliance, we hereby grant OTC Markets Group Inc. full and complete permission and right to publish this letter through the Service for viewing by the public and regulatory agencies; provided, that such permission shall not be deemed a waiver of the limitations of reliance set forth in this paragraph.

Very truly yours,

BARRY J. MILLER PLLC

By 
Barry J. Miller